
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/565166/publications.pdf Version: 2024-02-01



HENDRÃOE F LONES

#	Article	IF	CITATIONS
1	Caring for Families Impacted by Opioid Use: A Qualitative Analysis of Integrated Program Designs. Academic Pediatrics, 2022, 22, 125-136.	2.0	9
2	Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants. Journal of Perinatology, 2022, 42, 300-306.	2.0	11
3	Perspectives among Women Receiving Medications for Opioid use Disorder: Implications for Development of a Peer Navigation Intervention to Improve Access to Family Planning Services. Substance Abuse, 2022, 43, 722-732.	2.3	6
4	Increasing knowledge about recovery-related life domains among pregnant and parenting women in comprehensive substance use disorder treatment: The Art of Addiction Recovery Program. Drug and Alcohol Dependence, 2022, 232, 109252.	3.2	1
5	"You have to take this medication, but then you get punished for taking it:―lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period. Journal of Substance Abuse Treatment, 2022, 139, 108765.	2.8	26
6	Standardizing the Clinical Definition of Opioid Withdrawal in the Neonate. Journal of Pediatrics, 2022, 243, 33-39.e1.	1.8	28
7	Implementation of a Standardized Clinical Definition of Opioid Withdrawal in the Neonate. JAMA - Journal of the American Medical Association, 2022, , .	7.4	3
8	Reply. Journal of Pediatrics, 2022, , .	1.8	0
9	Improving access to care through Advanced Practice Registered Nurses: Focus on perinatal patients with Opioid Use Disorder. Journal of Advanced Nursing, 2021, 77, 4-10.	3.3	5
10	Sex and female empowerment (SAFE): A randomized trial comparing sexual health interventions for women in treatment for opioid use disorder. Drug and Alcohol Dependence, 2021, 221, 108634.	3.2	6
11	Development and Implementation of a Mobile Tool for High-Risk Pregnant Women to Deliver Effective Caregiving for Neonatal Abstinence Syndrome: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2021, 10, e27382.	1.0	1
12	Increasing access to family planning services among women receiving medications for opioid use disorder: A pilot randomized trial examining a peer-led navigation intervention. Journal of Substance Abuse Treatment, 2021, 126, 108318.	2.8	10
13	Challenges and opportunities during the COVID-19 pandemic: Treating patients for substance use disorders during the perinatal period. Preventive Medicine, 2021, 152, 106742.	3.4	9
14	The Stimulant Crisis Intertwined With the Opioid Crisis: A Compassionate Response for Dyadic Health and Well-Being. American Journal of Public Health, 2021, 111, 1436-1438.	2.7	0
15	Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100369.	2.6	2
16	Increasing Substance Use Disorder Treatment Professionals Knowledge: The Child Intervention for Living Drug-free (CHILD) Curriculum Journal of Substance Abuse and Alcoholism, 2021, 8, .	2.0	0
17	Buprenorphine-naloxone use in pregnancy: aÂsystematic review and metaanalysis. American Journal of Obstetrics & Gynecology MFM, 2020, 2, 100179.	2.6	35
18	Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality. Health Affairs, 2020, 39, 1395-1404.	5.2	25

#	Article	IF	CITATIONS
19	Letter-in-reply. Journal of Addiction Medicine, 2020, 14, 354-355.	2.6	0
20	Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemporary Clinical Trials, 2020, 93, 106014.	1.8	20
21	Perinatal Substance Use Disorders Treatment. North Carolina Medical Journal, 2020, 81, 36-40.	0.2	6
22	Drug Use Among Women and Children in Afghanistan: The Complexities of An Important Public Health Issue. HSOA Journal of Addiction & Addictive Disorders, 2020, 7, .	0.1	0
23	Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Clinical Therapeutics, 2019, 41, 1681-1689.	2.5	28
24	Shared Decisionâ€Making Tool for Treatment of Perinatal Opioid Use Disorder. Psychiatric Research and Clinical Practice, 2019, 1, 27-31.	2.4	22
25	Concurrent Opioid and Alcohol Use Among Women Who Become Pregnant: Historical, Current, and Future Perspectives. Substance Abuse: Research and Treatment, 2019, 13, 117822181985263.	0.9	1
26	Maternal buprenorphine treatment during pregnancy and maternal physiology. Drug and Alcohol Dependence, 2019, 201, 38-44.	3.2	2
27	Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. Clinics in Perinatology, 2019, 46, 349-366.	2.1	20
28	Prenatal Opioid Exposure, Neonatal Abstinence Syndrome/Neonatal Opioid Withdrawal Syndrome, and Later Child Development Research: Shortcomings and Solutions. Journal of Addiction Medicine, 2019, 13, 90-92.	2.6	40
29	The CHILD Intervention for Living Drug-Free Comprehensive Assessment of Risk, Resilience, and Experience (CHILD CARRE) Measure: Initial Findings. Journal of Child and Adolescent Substance Abuse, 2019, 28, 411-425.	0.5	1
30	Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure. American Journal on Addictions, 2018, 27, 92-96.	1.4	23
31	Comprehensive Women-Centered Treatment for Psychoactive Substance Use in the Republic of Georgia: Outcomes of a Randomized Clinical Trial. International Journal of Mental Health and Addiction, 2018, 16, 1249-1260.	7.4	2
32	Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. Drug and Alcohol Dependence, 2018, 185, 40-49.	3.2	105
33	In Reply. Obstetrics and Gynecology, 2018, 132, 1061-1062.	2.4	1
34	Neonatal abstinence syndrome. Nature Reviews Disease Primers, 2018, 4, 47.	30.5	33
35	Brief Report: Pregnancy intention and opioid use disorder treatment retention in the MOTHER study. American Journal on Addictions, 2018, 27, 372-374.	1.4	6
36	Stigmatizing Language About Neonatal Abstinence Syndrome. JAMA - Journal of the American Medical Association, 2018, 320, 723.	7.4	1

#	Article	IF	CITATIONS
37	Reconsidering retrospective review of neurodevelopmental outcomes in infants treated for neonatal abstinence syndrome. Journal of Perinatology, 2018, 38, 1280-1281.	2.0	4
38	Maternal buprenorphine treatment and fetal neurobehavioral development. American Journal of Obstetrics and Gynecology, 2017, 216, 529.e1-529.e8.	1.3	29
39	Medically Assisted Withdrawal (Detoxification): Considering the Mother-Infant Dyad. Journal of Addiction Medicine, 2017, 11, 90-92.	2.6	25
40	Pregnancy and the Opioid Epidemic. Current Treatment Options in Psychiatry, 2017, 4, 184-195.	1.9	4
41	A Comparison of Reinforcement Based Treatment (RBT) versus RBT plus Recovery Housing (RBTRH). Journal of Substance Abuse Treatment, 2017, 72, 48-55.	2.8	11
42	Implementation and Evaluation of an Intervention for Children in Afghanistan at Risk for Substance Use or Actively Using Psychoactive Substances. International Journal of Pediatrics (United Kingdom), 2017, 2017, 1-10.	0.8	6
43	Risk Factors for Substance Use Among Street Children Entering Treatment in India. Indian Journal of Psychological Medicine, 2016, 38, 419-423.	1.5	10
44	Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and metaâ€analysis of safety in the mother, fetus and child. Addiction, 2016, 111, 2115-2128.	3.3	191
45	Psychometric assessment of the Neonatal Abstinence Scoring System and the MOTHER NAS Scale. American Journal on Addictions, 2016, 25, 370-373.	1.4	39
46	Response to Smith and Brogly <i>et al</i> . commentaries on Zedler <i>et al</i> Addiction, 2016, 111, 2131-2133.	3.3	2
47	Neonatal Abstinence Syndrome. Journal of Addiction Medicine, 2016, 10, 224-228.	2.6	16
48	Measurement of neonatal abstinence syndrome: Evaluation of short forms. Journal of Opioid Management, 2016, 12, 19-23.	0.5	17
49	Little Fly Wing: a new drug of concern in Argentina. Addiction, 2015, 110, 1534-1535.	3.3	1
50	Feasibility and initial efficacy of a culturally sensitive women-centered substance use intervention in Georgia: Sex risk outcomes. Substance Abuse Treatment, Prevention, and Policy, 2015, 10, 47.	2.2	4
51	Comprehensive women-centered treatment for substance use disorders in Georgia: current status and future directions. Journal of Substance Use, 2015, 20, 367-374.	0.7	4
52	Correlates of Lifetime Trauma Exposure Among Pregnant Women from Cape Town, South Africa. International Journal of Mental Health and Addiction, 2015, 13, 307-321.	7.4	7
53	Comment on: Infants of opioid-dependent mothers: Neurodevelopment at six months. Early Human Development, 2015, 91, 243.	1.8	3
54	Neonatal abstinence syndrome: Historical perspective, current focus, future directions. Preventive Medicine, 2015, 80, 12-17.	3.4	61

#	Article	IF	CITATIONS
55	Initial Feasibility and Acceptability of a Comprehensive Intervention for Methamphetamine-Using Pregnant Women in South Africa. Psychiatry Journal, 2014, 2014, 1-8.	1.5	14
56	Process and Product in Cross-Cultural Treatment Research: Development of a Culturally Sensitive Women-Centered Substance Use Intervention in Georgia. Journal of Addiction, 2014, 2014, 1-12.	0.9	6
57	Commentary on Mactieret al. (2014): Methadone-assisted treatment and the complexity of influences on fetal development. Addiction, 2014, 109, 489-490.	3.3	1
58	Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence, 2014, 134, 414-417.	3.2	69
59	Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. American Journal of Obstetrics and Gynecology, 2014, 210, 302-310.	1.3	103
60	Cocaine, progesterone, and post-partum women. Lancet Psychiatry,the, 2014, 1, 323-324.	7.4	0
61	The relationship between maternal methadone dose at delivery and neonatal outcome: Methodological and design considerations. Neurotoxicology and Teratology, 2013, 39, 110-115.	2.4	43
62	Management of Acute Postpartum Pain in Patients Maintained on Methadone or Buprenorphine During Pregnancy. American Journal of Drug and Alcohol Abuse, 2009, 35, 151-156.	2.1	58